Overview
Who is it for?
The tool is intended for men with non-metastatic prostate cancer who are deciding between conservative and radical management regimes. The tool is not for use in cases where prostate cancer has spread beyond the prostate. The tool is also less well tested and likely to be less reliable in men with very high PSA, high grade group or high stage as very few men with these characteristics were managed with conservative management in our development or validation data.
Nothing can ever tell an individual man exactly what is going to happen to him in the future but this tool will provide a realistic estimate or ‘best guess’ about the potential survival benefits of different treatment options.
The web tool is not designed to give clinical advice and all decisions on treatment options must be made in consultation between the patient and a qualified doctor.
How Predict Prostate works
This short video may help explain how Predict Prostate works.
The estimates that Predict Prostate produces are based on observational data from thousands of men previously diagnosed with non-metastatic prostate cancer from the East of England, UK. It provides the average survival rate for men in the past of similar age and with similar characteristics.
These data were then used to help produce estimates of the potential outcomes for men who have prostate cancer now, depending on characteristics about them and their tumour. The model has also been tested among men diagnosed with prostate cancer in Singapore. It has been checked to make sure that the estimates it produces are as accurate as they can be given current nowledge. It is important to note that the model can only give an estimate of what may happen and cannot say with certainty whether an individual patient will survive their cancer or not.
has more detail on how Predict Prostate was developed and tested.
Who built Predict Prostate?
Predict Prostate has been developed by a partnership between the Academic Urology Group and the Centre for Cancer Genetic Epidemiology at the University of Cambridge in collaboration with the National Cancer Registration and Analysis Service (NCRAS) at Public Health England. This work has been supported by funding from The Urology Foundation and the Evelyn Trust.
The website has been built by the Winton Centre for Risk & Evidence Communication at the University of Cambridge who are funded by a generous donation from the David and Claudia Harding Foundation and the Winton Charitable Foundation.
v-1.1-1.17-1-gb1f94fd0
